- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Genomics in the Management of Advanced Bladder Cancer
Authors
Keywords
Bladder cancer, Urothelial carcinoma, Genomics, Genome sequencing, Mutations, Molecular targets, Targeted therapy, Chemotherapy, Platinum
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-02-03
DOI
10.1007/s11864-014-0319-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy
- (2014) W. T. Kim et al. ANNALS OF ONCOLOGY
- Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study
- (2014) Christopher M. Booth et al. CANCER
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Targeted therapies in urothelial carcinoma
- (2014) Monalisa Ghosh et al. CURRENT OPINION IN ONCOLOGY
- Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
- (2014) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
- (2014) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis
- (2014) Jaime Acquaviva et al. MOLECULAR CANCER RESEARCH
- FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism
- (2014) Jaime Acquaviva et al. MOLECULAR CANCER RESEARCH
- Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
- (2014) Woonyoung Choi et al. Nature Reviews Urology
- Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder
- (2014) Nikhil Sapre et al. PATHOLOGY
- Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer
- (2014) Carl D. Morrison et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Why is perioperative chemotherapy for bladder cancer underutilized?
- (2014) Francis M. Patafio et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
- (2014) Elizabeth A. Guancial et al. Cancer Medicine
- Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host
- (2013) D. J. Gallagher et al. ANNALS OF ONCOLOGY
- Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
- (2013) Holger Gerullis et al. ANTI-CANCER DRUGS
- Phase II study of everolimus in metastatic urothelial cancer
- (2013) Matthew I. Milowsky et al. BJU INTERNATIONAL
- Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
- (2013) Susanne Krege et al. BJU INTERNATIONAL
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis
- (2013) Firas Abdollah et al. Cancer Epidemiology
- Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
- (2013) R. Morales-Barrera et al. Clinical & Translational Oncology
- A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
- (2013) Roberto Pili et al. Clinical Genitourinary Cancer
- Actionable mutations in muscle-invasive bladder cancer
- (2013) Richard M. Bambury et al. CURRENT OPINION IN UROLOGY
- Second-line systemic therapy for metastatic urothelial carcinoma of the bladder
- (2013) Christina Ann Ortmann et al. Future Oncology
- Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes
- (2013) Claire F. Taylor et al. HUMAN MOLECULAR GENETICS
- Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
- (2013) Arjun V. Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
- (2013) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
- (2013) Guangwu Guo et al. NATURE GENETICS
- Frequent truncating mutations of STAG2 in bladder cancer
- (2013) David A Solomon et al. NATURE GENETICS
- Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
- (2013) Cristina Balbás-Martínez et al. NATURE GENETICS
- Molecular targets on the horizon for kidney and urothelial cancer
- (2013) Joaquim Bellmunt et al. Nature Reviews Clinical Oncology
- Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
- (2012) E. Seront et al. ANNALS OF ONCOLOGY
- miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer
- (2012) Iver Nordentoft et al. BMC Medical Genomics
- Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
- (2012) Markus Riester et al. CLINICAL CANCER RESEARCH
- Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer
- (2012) Matthew D. Galsky et al. Clinical Genitourinary Cancer
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Oncogenic FGFR3 gene fusions in bladder cancer
- (2012) Sarah V. Williams et al. HUMAN MOLECULAR GENETICS
- High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues
- (2012) Alcides Chaux et al. HUMAN PATHOLOGY
- Cancer Genomics: Technology, Discovery, and Translation
- (2012) Ben Tran et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- (2012) Andrea Necchi et al. LANCET ONCOLOGY
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
- (2011) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
- (2011) Achim Fleischmann et al. EUROPEAN UROLOGY
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
- (2011) Noah M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
- (2011) Yaoting Gui et al. NATURE GENETICS
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
- (2010) Srikala S. Sridhar et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
- (2010) David J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer
- (2009) Robert Dreicer et al. CANCER
- Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion
- (2009) Manoj Garg et al. EUROPEAN JOURNAL OF CANCER
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
- (2008) Guru Sonpavde et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started